Nairametrics
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Nairalytics
    • Macro-Economic News
    • Research Analysis
    • Budget
    • Public Debt
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
  • 2023 Elections
No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Nairalytics
    • Macro-Economic News
    • Research Analysis
    • Budget
    • Public Debt
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
  • 2023 Elections
No Result
View All Result
Nairametrics
No Result
View All Result
Home Business News Coronavirus

AstraZeneca seeks emergency use authorization of covid prophylaxis drug in U.S

Chidinma AnyalewechibyChidinma Anyalewechi
1 year ago
in Coronavirus
Covid-19: Second dose of AstraZeneca vaccine can offer 90% protection – Study
Share on FacebookShare on TwitterShare on Linkedin

On Tuesday, drugmaker AstraZeneca announced that it has requested an emergency use authorization grant from the U.S. Food and Drug Administration (FDA) for its Covid-19 prophylaxis drug.

This comes a month after the antibody cocktail was proven to be effective in the prevention of Covid symptoms among people highly at risk to be infected who received the drug prior to exposure, according to Forbes.

According to the company in a press release, its Phase III trial featuring over 5,000 participants revealed that the antibody cocktail was 77% effective in people who received the drug as a preventive measure by reducing the risk of developing Covid-19 symptoms.

The drug was developed as an antibody treatment that uses lab-made antibodies that can stay for months in the recipient’s body and protect them against infection.

It is, however, important to note that antibody treatments are not vaccines. Unlike antibody treatments, vaccines help a recipient’s immune system build its own antibodies and infection-fighting cells against the virus.

According to AstraZeneca, the antibody treatment is effective in protecting people who may not develop a robust immune response to Covid-19 vaccines.

In addition, the company noted that trials performed in Vitro, i.e in test tubes showed that the drug was able to neutralize emergent Covid variants, including delta and mu, adding that supply agreements for the antibody cocktail are in the works with the United States and other governments.

As stated by Astrazeneca’s chief of research and development, Mene Pangalos: “Vulnerable populations such as the immunocompromised often aren’t able to mount a protective response following vaccination and continue to be at risk of developing COVID-19. With this first global regulatory filing, we are one step closer to providing an additional option to help protect against COVID-19 alongside vaccines.”

Recall that, in June 2021, a trial of AstraZeneca’s antibody therapy among patients exposed to the virus failed to prevent symptoms. The effectiveness of the drug among people already exposed to the virus was only 33%, including exposed individuals who tested negative.

Related

Tags: AstraZenecaCovid-19Vaccine

Leave a Reply Cancel reply

Press one
hfm
Mega Millions
fidelity banner
SME
HFM
Patricia





NM newsletters

Business News | Stock Market | Money Market | Cryptos | Financial Literacy | SME |

Recent News

  • Former Chief of General Staff under Abacha regime, Oladipo Diya, is dead
  • FUGAZ investors gain N34.1 billion during the week 
  • FG highlights policies developed to drive MSMEs growth in Nigeria 

Follow us on social media:

Recent News

Nigeria’s Former Chief of General Staff, Oladipo Diya, is dead

Former Chief of General Staff under Abacha regime, Oladipo Diya, is dead

March 26, 2023
FUGAZ investors gain N34.1 billion during the week 

FUGAZ investors gain N34.1 billion during the week 

March 26, 2023
  • Home
  • Exclusives
  • Markets
  • Industries
  • Economy
  • Business News
  • Financial Literacy
  • Lifestyle
  • Opinions
  • 2023 Elections

© 2023 Nairametrics

No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Nairalytics
    • Macro-Economic News
    • Research Analysis
    • Budget
    • Public Debt
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
  • 2023 Elections

© 2023 Nairametrics

error: Alert: Content selection is disabled!!